Prot# MGL-3196-14: A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1)

Project: Research project

Project Details

StatusActive
Effective start/end date7/28/207/28/23

Funding

  • Pharmaceutical Research Associates, Inc. (Prot# MGL-3196-14)
  • Madrigal Pharmaceuticals, Inc. (Prot# MGL-3196-14)